Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00798694 · ClinicalTrials.gov registry record · Phase 4
How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?
A Phase 4 study of Glaucoma, sponsored by Wills Eye.
- Completed
- Registry status
- Phase 4
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT00798694: Completed Phase 4 study of Glaucoma, sponsored by Wills Eye.
NCT00798694 is a Phase 4 study of Glaucoma that has completed, run by Wills Eye. The registered enrollment target is 58 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00798694, a Phase 4 study of Glaucoma, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine whether one glaucoma eye drop is less likely to cause changes to the surface of the eye (conjunctiva) than another. The two different prostaglandins are Xalatan and Travatan Z.
Primary Outcome
Difference of tear break up time (in seconds, average of 3 measurements) at one and two months after enrollment.
Conditions Studied
Interventions
- DRUG Xalatan
- DRUG Travatan Z
Study Locations (1)
Pennsylvania
- Wills Eye Glaucoma Service - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-02 |
| Phase | Phase 4 |
What the finished NCT00798694 record still lists
NCT00798694 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Xalatan is the first listed.
NCT00798694 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00798694 about?
NCT00798694 is a clinical study titled "How Similar Are Changes to the Surface of the Eye When Two Different Glaucoma Eye Drops Are Used?". To determine whether one glaucoma eye drop is less likely to cause changes to the surface of the eye (conjunctiva) than another. The two different prostaglandins are Xalatan and Travatan Z.
What is the current status of trial NCT00798694?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 58 participants. The study started on 2008-11. Estimated completion is 2011-02.
What conditions does trial NCT00798694 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT00798694?
The interventions under investigation include: Xalatan (DRUG), Travatan Z (DRUG).
Who is sponsoring clinical trial NCT00798694?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00798694 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00798694's enrollment target sits among peer trials
58 60th of 92 higher than 33 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Retinal Blood Flow and Autoregulation
RECRUITING · Phase 4
-
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
RECRUITING · Phase 4
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
COMPLETED · Phase 4
-
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
COMPLETED · Phase 4
-
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia